2024
Influence of lamina propria invasion extension on T1 high‐grade non‐muscle‐invasive bladder cancer in patients undergoing BCG or radical cystectomy
Contieri R, Tan W, Grajales V, Hensley P, Martini A, Bree K, Myers A, Nogueras‐Gonzalez G, Navai N, Dinney C, Guo C, Kamat A. Influence of lamina propria invasion extension on T1 high‐grade non‐muscle‐invasive bladder cancer in patients undergoing BCG or radical cystectomy. BJU International 2024, 133: 733-741. PMID: 38374533, DOI: 10.1111/bju.16293.Peer-Reviewed Original ResearchConceptsNon-muscle-invasive bladder cancerImmediate radical cystectomyCancer-specific survivalMetastasis-free survivalProgression-free survivalT1 substagingOverall survivalRadical cystectomyPathology reportsBladder cancerHigh-grade non-muscle-invasive bladder cancerPatients treated with bacillus Calmette-GuerinAssociated with poor progression-free survivalInstitutional review board-approved retrospective studyPatients treated with BCGPoor progression-free survivalLamina propriaAssociated with upstagingBCG-treated patientsCalculate overall survivalTreated with BCGKaplan-Meier methodHigh-grade patientsMultivariate Cox modelInvasive characteristics
2022
Adverse cardiovascular events and mortality in men during testosterone treatment: an individual patient and aggregate data meta-analysis
Hudson J, Cruickshank M, Quinton R, Aucott L, Aceves-Martins M, Gillies K, Bhasin S, Snyder P, Ellenberg S, Grossmann M, Travison T, Gianatti E, van der Schouw Y, Emmelot-Vonk M, Giltay E, Hackett G, Ramachandran S, Svartberg J, Hildreth K, Antonic K, Brock G, Tenover J, Tan H, Kong C, Tan W, Marks L, Ross R, Schwartz R, Manson P, Roberts S, Andersen M, Magnussen L, Hernández R, Oliver N, Wu F, Dhillo W, Bhattacharya S, Brazzelli M, Jayasena C. Adverse cardiovascular events and mortality in men during testosterone treatment: an individual patient and aggregate data meta-analysis. The Lancet Healthy Longevity 2022, 3: e381-e393. PMID: 35711614, PMCID: PMC9184259, DOI: 10.1016/s2666-7568(22)00096-4.Peer-Reviewed Original ResearchConceptsRisk of biasMeta-analysisStudy designSystematic reviewInclusion criteriaCochrane Database of Systematic ReviewsCochrane risk of bias toolDatabase of Systematic ReviewsRisk of bias toolMEDLINE In-Process & Other Non-Indexed CitationsIn-Process & Other Non-Indexed CitationsTwo-stage meta-analysisCharacteristics of interventionsOther Non-Indexed CitationsMeta-analysis of randomised controlled trialsOne-stage meta-analysisFull-text screeningRandomised controlled trialsNon-Indexed CitationsCardiovascular eventsAggregate data meta-analysisCoronary heart diseaseData meta-analysisPeer-reviewed publicationsCochrane Controlled Trials Register
2021
Recovery of health‐related quality of life in patients undergoing robot‐assisted radical cystectomy with intracorporeal diversion
Abozaid M, Tan W, Khetrapal P, Baker H, Duncan J, Sridhar A, Briggs T, Selim M, Abdallah M, Elmahdy A, Elserafy F, Kelly J. Recovery of health‐related quality of life in patients undergoing robot‐assisted radical cystectomy with intracorporeal diversion. BJU International 2021, 129: 72-79. PMID: 34092021, DOI: 10.1111/bju.15505.Peer-Reviewed Original ResearchConceptsGlobal HRQoL scoreHealth-related quality of lifeRobot-assisted radical cystectomyEORTC QLQ-C30HRQoL scoresQuality of lifeSexual functionRadical cystectomyUrinary diversionIleal conduitIC patientsRecovery of health-related quality of lifeFunction scoresClavien-Dindo complicationsHealth-related qualityPhysical function scoresRehabilitation of sexual functionIntracorporeal urinary diversionLongitudinal analysisSexual function scoresEuropean Organisation for ResearchMonths follow-upEORTC QLQ-BLM30Higher sexual function scoresReturn to baseline
2020
Evaluation of the New American Urological Association Guidelines Risk Classification for Hematuria
Woldu S, Ng C, Loo R, Slezak J, Jacobsen S, Tan W, Kelly J, Lough T, Darling D, van Kessel K, de Jong J, van Criekinge W, Shariat S, Hiar A, Brown S, Boorjian S, Barocas D, Svatek R, Lotan Y. Evaluation of the New American Urological Association Guidelines Risk Classification for Hematuria. Journal Of Urology 2020, 205: 1387-1392. PMID: 33356483, DOI: 10.1097/ju.0000000000001550.Peer-Reviewed Original ResearchConceptsIncidence of bladder cancerBladder cancerHigh-risk groupRisk groupsRisk strataCancer incidenceDegree of hematuriaHigh-risk patientsRisk stratification systemAmerican Urological AssociationEvaluation of patientsMultinational cohort studyRisk-stratified approachBladder cancer incidenceHematuria patientsClinically meaningful categoriesGross hematuriaUrologic evaluationIntermediate riskProspective registryRisk patientsContemporary patientsSmoking historyUrological AssociationHematuriaMorbidity and mortality after robot‐assisted radical cystectomy with intracorporeal urinary diversion in octogenarians: results from the European Association of Urology Robotic Urology Section Scientific Working Group
Mortezavi A, Crippa A, Edeling S, Pokupic S, Dell’Oglio P, Montorsi F, D'Hondt F, Mottrie A, Decaestecker K, Wijburg C, Collins J, Kelly J, Tan W, Sridhar A, John H, Canda A, Schwentner C, Rönmark E, Wiklund P, Hosseini A. Morbidity and mortality after robot‐assisted radical cystectomy with intracorporeal urinary diversion in octogenarians: results from the European Association of Urology Robotic Urology Section Scientific Working Group. BJU International 2020, 127: 585-595. PMID: 33058469, PMCID: PMC8246851, DOI: 10.1111/bju.15274.Peer-Reviewed Original ResearchConceptsPatients aged <Intracorporeal urinary diversionCancer-specific mortalityOther-cause mortalityPostoperative complicationsRadical cystectomyMortality rateUrinary diversionBladder cancerOutcomes of patients aged <Predictor of high-grade complicationsHigh-grade complication rateOther-cause mortality ratesRobot-assisted radical cystectomyMultivariate logistic regression analysisClavien-Dindo gradeLaparoscopic radical cystectomyHigh-grade complicationsPostoperative mortality rateMinimally invasive approachTreatment-related risksLogistic regression analysisOCM ratesPostoperative variablesComplication rateDelayed blood transfusion is associated with mortality following radical cystectomy
Tan W, Wang Y, Trinh Q, Preston M, Kelly J, Hrouda D, Kibel A, Krasnow R, Liu J, Chung B, Chang S, Mossanen M. Delayed blood transfusion is associated with mortality following radical cystectomy. Scandinavian Journal Of Urology 2020, 54: 290-296. PMID: 32538224, DOI: 10.1080/21681805.2020.1777195.Peer-Reviewed Original ResearchConceptsDelayed blood transfusionEarly blood transfusionBlood transfusionRadical cystectomyBladder cancer treated with radical cystectomyPatients treated with radical cystectomyAssociated with 90-day mortalityIncreased 90-day mortalityTime of blood transfusionPrimary end pointRetrospective cohort studyMultivariate logistic regressionAssociated with mortalityDelayed transfusionMedian ageClinical deteriorationCystectomyHigher CCIOlder patientsTransfusionCohort studyEnd pointsPatient mortalityPatientsIndex admissionInequity in selective referral to high-volume hospitals for genitourinary malignancies
Berg S, Tully K, Sahraoui A, Tan W, Krimphove M, Marchese M, Lipsitz S, Noldus J, Trinh Q. Inequity in selective referral to high-volume hospitals for genitourinary malignancies. Urologic Oncology Seminars And Original Investigations 2020, 38: 582-589. PMID: 32217041, DOI: 10.1016/j.urolonc.2020.02.013.Peer-Reviewed Original ResearchConceptsHigh-volume hospitalsBladder cancerPredictors of treatmentCancer patientsRadical prostatectomyProstate cancerMuscle-invasive urothelial bladder cancerNegative predictors of treatmentBlack raceNational Cancer DatabaseNonmetastatic prostate cancerUrothelial bladder cancerProstate cancer patientsBladder cancer patientsMultivariate logistic regression modelAssociated with lower ratesKidney cancer patientsPrivate insurance statusAssociated with lower oddsAssociated with greater oddsLow-volume hospitalsRadical cystectomyReceipt of treatmentGenitourinary malignanciesPerioperative morbidityExploring patients’ experience and perception of being diagnosed with bladder cancer: a mixed‐methods approach
Tan W, Teo C, Chan D, Ang K, Heinrich M, Feber A, Sarpong R, Williams N, Brew‐Graves C, Ng C, Kelly J, Khetrapal P, Sridhar A, Baker H, Ocampo F, Whotton N, Dent K, Pearson S, Hatton J, Newton M, Heeney E, Green K, Evans S, Rogers M, Dann A, Cook J, Cornwell M, Mills R, Knight H, Maher S, Rane A, Thomas S, Reyner S, Vallejera G, Adeniran P, Masood S, Ridgway S, Coulding M, Savill H, Mccormick J, Clark M, Collins G, Jewers K, Keith S, Bowen G, Hargreaves J, Riley K, Srirangam S, Mistry R, Chadwick J, Cocks S, Hull R, Loftus A, Dawson L, Roberts H, Main C, Jain S, Waymont C, Rogers J, Grant A, Carter V, Heap H, Lomas C, Cooke P, Baird Y, Moore S, Greenslade S, Margalef J, Chadbourn I, Harris M, Hicks J, Clitheroe P, Connolly S, Hodgkinson S, Haydock H, Sinclair A, Storr E, Cogley L, Natale S, Lovegrove W, Smith S, Smith K, Hewitt D, Sriram R, Atkinson K, Royle L, Madine J, MacLean K, Walsh J, Guerdette A, Hill M, Payne D, Power A, Cannon J, Devereaux L, Thompson A, Scarratt L, Hodgkiss T, Johnstone D, Johnson J, Allsop J, Rothwell J, Connolly K, Cherian J, Wardle H, Wilson D, Bayles A, Pelluri S, Pati J, Gherman A, Scott C, Madaan S, Taylor J, Edmunds E, Moore J, Rees A, Williams S, Caddy S, Dukes S, Goffe A, Buckhorn K, Nichols L, Acher P, Baillie K, Middleton K, Proctor C, Cresswell J, Chilvers A, Cain M, Vaux A, Watson D, Bradfield S, Gregory H, Mostafid H, Kehoe L, Drakeley S, Davies J, Williamson L, Krishnan R, Lunt N, Hill P, Burns H, Townley B, Wilkinson L, Wassall H, Sinclair A, Hunt J, Holbrook B, Stancombe L, Morrison J, Vankoutrik L, Misra S, Fossey G, Richards A, Mcdonald K, Henderson A, Fennelly R, Tribbeck M, Ames K, Borwell J, Kotze M, Beesley K, Rennie K, Porter T, Gipson A, Piper L, Bailey L, Chrisopoulou A, Slevin K, McCartin F, Warburton H, Hathaway‐Lees S, Whetton K, Delves G, Day A, Bankole T, Broadhead S, Malde S, Oblak M, Ellis D, Bishara S, Barias‐Lara T, Donkov I, Thatcher H, Morris H, Culmsee C, Menzies A, Bartlett C, Cutting C, O'Brien N, Jannapureddy R, Kelkar A, Fitzgerald J, Longhurst S, Worth C, Peracha A, Mzazi S, Poile C, Griffiths L, Cook A, Barber N, Brar N, Alty A, Zelhof B, Blades R. Exploring patients’ experience and perception of being diagnosed with bladder cancer: a mixed‐methods approach. BJU International 2020, 125: 669-678. PMID: 31975539, PMCID: PMC7318301, DOI: 10.1111/bju.15008.Peer-Reviewed Original ResearchConceptsNon-muscle-invasive bladder cancer diagnosisPatient experienceNon-muscle-invasive bladder cancerTransurethral resection of bladder tumorCancer diagnosisBrief IPQMixed-methods approachBrief Illness Perception QuestionnaireCause of bladder cancerRisk of bladder cancerMental health of patientsIllness Perception QuestionnairePersonal controlBladder cancerHealth of patientsSemi-structured interviewsPerception of disease controlLow personal controlMental healthProspective multicentre observational studyPsychological supportUrine biomarker studiesPerception QuestionnaireDiagnosis of non-muscle-invasive bladder cancerPoor perception
2019
Effects of Bladder Cancer on UK Healthcare Costs and Patient Health-Related Quality of Life: Evidence From the BOXIT Trial
Cox E, Saramago P, Kelly J, Porta N, Hall E, Tan W, Sculpher M, Soares M. Effects of Bladder Cancer on UK Healthcare Costs and Patient Health-Related Quality of Life: Evidence From the BOXIT Trial. Clinical Genitourinary Cancer 2019, 18: e418-e442. PMID: 32144049, PMCID: PMC7427321, DOI: 10.1016/j.clgc.2019.12.004.Peer-Reviewed Original ResearchConceptsHealth-related quality of lifeNon-muscle-invasive bladder cancerMuscle-invasive bladder cancerProgression to muscle-invasive bladder cancerQuality of lifePatients' health-related quality of lifePatients' health-related qualityBladder cancerHealth-related qualityEQ-5D-3LGeneralized estimating equationsUK unit costsRandomized controlled trialsHRQoL decrementNon-muscle-invasive bladder cancer patientsHRQoLHealthcare costsHRQOL effectsLimited evidenceControlled trialsEstimating equationsTMN classificationClinical eventsAverage costRecurrenceVariation in Positive Surgical Margin Status After Radical Prostatectomy for pT2 Prostate Cancer
Tan W, Krimphove M, Cole A, Marchese M, Berg S, Lipsitz S, Löppenberg B, Nabi J, Abdollah F, Choueiri T, Kibel A, Sooriakumaran P, Trinh Q. Variation in Positive Surgical Margin Status After Radical Prostatectomy for pT2 Prostate Cancer. Clinical Genitourinary Cancer 2019, 17: e1060-e1068. PMID: 31303561, DOI: 10.1016/j.clgc.2019.06.008.Peer-Reviewed Original ResearchConceptsPositive surgical marginsFactors associated with positive surgical marginsPositive surgical margin statusPT2 prostate cancerRadical prostatectomyProstate cancerCancer-specific factorsSurgical approachMargin statusHigher hospital surgical volumeSurgical margin statusNational Cancer DatabaseHospital surgical volumeCancer-specific featuresPSM rateSurgical marginsCancer DatabaseImprove patient outcomesEvaluating patientsContribution of patientLogistic regression modelsSurgical volumeProstatectomyPatientsPatient-specificPathological Findings and Magnetic Resonance Imaging Concordance at Salvage Radical Prostatectomy for Local Recurrence following Partial Ablation Using High Intensity Focused Ultrasound.
Thompson J, Sridhar A, Tan W, Freeman A, Haider A, Allen C, Moore C, Orczyk C, Mazzon G, Khetrapal P, Shaw G, Rajan P, Mohammed A, Briggs T, Nathan S, Kelly J, Sooriakumaran P. Pathological Findings and Magnetic Resonance Imaging Concordance at Salvage Radical Prostatectomy for Local Recurrence following Partial Ablation Using High Intensity Focused Ultrasound. Journal Of Urology 2019, 201: 1134-1143. PMID: 30730409, DOI: 10.1097/ju.0000000000000135.Peer-Reviewed Original ResearchConceptsSalvage robot-assisted radical prostatectomyRobot-assisted radical prostatectomyPositive surgical marginsSalvage prostatectomyRadical prostatectomySensitivity of magnetic resonance imagingField recurrenceMagnetic resonance imagingInfield recurrenceSurgical marginsHigher risk of positive surgical marginsGleason 3+3 diseasePrimary robotic assisted radical prostatectomyRisk of positive surgical marginsMagnetic resonance imaging concordancePositive surgical margin ratePartial ablationSalvage radical prostatectomyMagnetic resonance imaging sensitivityResonance imagingSurgical margin rateRisk of recurrenceCharacteristics of recurrenceProstatectomy histopathologyHigh-intensity focused ultrasoundExamining the relationship between complications and perioperative mortality following radical cystectomy: a population‐based analysis
Mossanen M, Krasnow R, Zlatev D, Tan W, Preston M, Trinh Q, Kibel A, Sonpavde G, Schrag D, Chung B, Chang S. Examining the relationship between complications and perioperative mortality following radical cystectomy: a population‐based analysis. BJU International 2019, 124: 40-46. PMID: 30499636, DOI: 10.1111/bju.14636.Peer-Reviewed Original ResearchConceptsRadical cystectomyPerioperative mortalityPostoperative mortalityIncidence of perioperative complicationsTreated with RCPremier Healthcare DatabaseNature of complicationsIncreasing predicted probabilityOdds of mortalityProbability of mortalityReadmission complicationsRenal-relatedSurgical characteristicsPerioperative complicationsBladder cancerPrimary outcomeComplicationsHealthcare databasesPatientsMortalityCystectomyMultivariate regressionReadmissionHospitalisationHospitalMixed‐methods approach to exploring patients’ perspectives on the acceptability of a urinary biomarker test in replacing cystoscopy for bladder cancer surveillance
Tan W, Teo C, Chan D, Heinrich M, Feber A, Sarpong R, Allan J, Williams N, Brew‐Graves C, Ng C, Kelly J, Khetrapal P, ridhar A, Baker H, Ocampo F, Whotton N, Dent K, Pearson S, Hatton J, Newton M, Heeney E, Green K, Evans S, Rogers M, Dann A, Cook J, Cornwell M, Mills R, Knight H, Maher S, Rane A, Thomas S, Reyner S, Vallejera G, Adeniran P, Masood S, Ridgway S, Coulding M, Savill H, Mccormick J, Clark M, Collins G, Jewers K, Keith S, Bowen G, Hargreaves J, Riley K, Srirangam S, Mistry R, Chadwick J, Cocks S, Hull R, Loftus A, Dawson L, Roberts H, Main C, Jain S, Waymont C, Rogers J, Grant A, Carter V, Heap H, Lomas C, Cooke P, Baird Y, Moore S, Greenslade S, Margalef J, Chadbourn I, Harris M, Hicks J, Clitheroe P, Connolly S, Hodgkinson S, Haydock H, inclair A, Storr E, Cogley L, Natale S, Lovegrove W, Smith S, Smith K, Hewitt D, Sriram R, Atkinson K, Royle L, Madine J, MacLean K, Walsh J, Guerdette M, Hill M, Payne D, Power A, Cannon J, Devereaux L, Thompson A, Scarratt L, Hodgkiss T, Johnstone D, Johnson J, Allsop J, Rothwell J, Connolly K, Cherian J, Wardle H, Wilson D, Bayles A, Pelluri S, Pati J, Gherman A, Scott C, Madaan S, Taylor A, Edmunds E, Moore J, Rees A, Williams S, Caddy S, Dukes S, Goffe A, Buckhorn K, Nichols L, Acher P, Baillie K, Middleton K, Proctor C, Cresswell J, Chilvers A, Cain M, Vaux A, Watson D, Bradfield S, Gregory H, Mostafid H, Kehoe L, Drakeley S, Davies A, Williamson L, Krishnan R, Lunt N, Hill P, Burns H, Townley B, Wilkinson L, Wassall H, Hunt J, Holbrook B, Stancombe L, Morrison J, Vankoutrik L, Misra S, Fossey G, Richards A, Mcdonald K, Henderson A, Fennelly R, Tribbeck M, Ames K, Borwell J, Kotze M, Beesley K, Rennie K, Porter T, Gipson A, Piper L, Bailey L, Chrisopoulou A, Slevin K, McCartin F, Warburton H, Hathaway‐Lees S, Whetton K, Delves G, Day A, Bankole T, Broadhead S, Malde S, Oblak M, Ellis D, Bishara S, Barias‐Lara T, Donkov I, Thatcher H, Morris M, Culmsee C, Menzies H, Bartlett C, Cutting C, O'Brien N, Jannapureddy R, Kelkar A, Fitzgerald J, Longhurst S, Worth C, Peracha M, Mzazi S, Poile C, Griffiths L, Cook A, Barber N, Brar N, lty A, Zelhof B, Blades R. Mixed‐methods approach to exploring patients’ perspectives on the acceptability of a urinary biomarker test in replacing cystoscopy for bladder cancer surveillance. BJU International 2019, 124: 408-417. PMID: 30694612, PMCID: PMC6767410, DOI: 10.1111/bju.14690.Peer-Reviewed Original ResearchConceptsMinimally acceptable sensitivityAdverse eventsMixed-methods approachUrine biomarkersUrinary biomarkersProspective multicentre observational studyUrinary biomarker testsUrinary tract symptomsHome to hospitalAssociated with adverse eventsUrinary tract infectionHigh-risk patientsMulticentre observational studySensitivity of cystoscopyBladder cancer surveillanceDiagnosis of cancerSemi-structured interviewsPrevalence of haematuriaPatient experiencePatient perspectivePatients' viewsCancer surveillanceTract infectionsUrine biomarker studiesPatient demographicsDevelopment and validation of a haematuria cancer risk score to identify patients at risk of harbouring cancer
Tan W, Ahmad A, Feber A, Mostafid H, Cresswell J, Fankhauser C, Waisbrod S, Hermanns T, Sasieni P, Kelly J, Khetrapal P, Baker H, Sridhar A, Lamb B, Ocampo F, McBain H, Baillie K, Middleton K, Watson D, Knight H, Maher S, Rane A, Pathmanathan B, Harmathova A, Hellawell G, Pelluri S, Pati J, Cossons A, Scott C, Madaan S, Bradfield S, Wakeford N, Dann A, Cook J, Cornwell M, Mills R, Thomas S, Reyner S, Vallejera G, Adeniran P, Masood S, Whotton N, Dent K, Pearson S, Hatton J, Newton M, Heeney E, Green K, Evans S, Rogers M, Gupwell K, Whiteley S, Brown A, McGrath J, Lunt N, Hill P, Sinclair A, Paredes‐Guerra A, Holbrook B, Ong E, Wardle H, Wilson D, Bayles A, Fennelly R, Tribbeck M, Ames K, Davies M, Taylor J, Edmunds E, Moore J, Mckinley S, Nolan T, Speed A, Tunnicliff A, Fossey G, Williams A, George M, Hutchins I, Einosas R, Richards A, Henderson A, Appleby B, Kehoe L, Gladwell L, Drakeley S, Davies J, Krishnan R, Roberts H, Main C, Jain S, Dumville J, Wilkinson N, Taylor J, Thomas F, Goulden K, Vinod C, Green E, Waymont C, Rogers J, Grant A, Carter V, Heap H, Lomas C, Cooke P, Scarratt L, Hodgkiss T, Johnstone D, Johnson J, Allsop J, Rothwell J, Connolly K, Cherian J, Ridgway S, Coulding M, Savill H, Mccormick J, Clark M, Collins G, Jewers K, Keith S, Bowen G, Hargreaves J, Riley K, Srirangam S, Rees A, Williams S, Dukes S, Goffe A, Dawson L, Mistry R, Chadwick J, Cocks S, Hull R, Loftus A, Baird Y, Moore S, Greenslade S, Margalef J, Chadbourn I, Harris M, Hicks J, Clitheroe P, Connolly S, Hodgkinson S, Haydock H, Sinclair A, Storr E, Cogley L, Natale S, Lovegrove W, Slack K, Nash D, Smith K, Walsh J, Guerdette A, Hill M, Payne D, Taylor B, Sinclair E, Perry M, Debbarma M, Hewitt D, Sriram R, Power A, Cannon J, Devereaux L, Thompson A, Atkinson K, Royle L, Madine J, MacLean K, Sarpong R, Brew‐Graves C, Williams N. Development and validation of a haematuria cancer risk score to identify patients at risk of harbouring cancer. Journal Of Internal Medicine 2019, 285: 436-445. PMID: 30521125, PMCID: PMC6446724, DOI: 10.1111/joim.12868.Peer-Reviewed Original ResearchConceptsCancer risk scoreNational Institute for Health and Clinical Excellence guidelinesRisk scoreInvestigation of haematuriaPhysician decision-makingAge-specific thresholdsValidation cohortExcellence guidelinesUK hospitalsAmerican Urological Association guidelinesNational guidelinesImprove patientNo significant overfittingImprove patient selectionUpper tract cancerLack of consensusAssociation guidelinesSmoking historySwiss patientsCohortPatient ageDevelopment cohortPatient selectionGuidelinesHaematuria
2018
Evaluating the cost of surveillance for non-muscle-invasive bladder cancer: an analysis based on risk categories
Mossanen M, Wang Y, Szymaniak J, Tan W, Huynh M, Preston M, Trinh Q, Sonpavde G, Kibel A, Chang S. Evaluating the cost of surveillance for non-muscle-invasive bladder cancer: an analysis based on risk categories. World Journal Of Urology 2018, 37: 2059-2065. PMID: 30446799, DOI: 10.1007/s00345-018-2550-x.Peer-Reviewed Original ResearchConceptsBladder cancerProgression to muscle-invasive diseaseNon-muscle-invasive bladder cancerHigh-risk disease patientsEORTC risk calculatorHigh-risk NMIBCManagement of NMIBCMuscle-invasive diseaseLow-risk tumorsBiologically heterogeneous diseaseHigh-risk diseaseSurveillance of patientsMethodsA Markov modelLong-term surveillanceHigh-risk groupPatient risk groupsOverall cost of careCost of surveillanceCost of careIntermediate-riskSurveillance cystoscopyExpensive malignanciesIndex patientPatient basisNMIBCPropensity-score-matched comparison of soft tissue surgical margins status between open and robotic-assisted radical cystectomy
Moschini M, Soria F, Mathieu R, Xylinas E, D'Andrea D, Tan W, Kelly J, Simone G, Tuderti G, Meraney A, Krishna S, Konety B, Zamboni S, Baumeister P, Mattei A, Briganti A, Montorsi F, Galucci M, Rink M, Karakiewicz P, Rouprêt M, Aziz A, Perry M, Rowe E, Koupparis A, Kassouf W, Scherr D, Ploussard G, Boorjian S, Sooriakumaran P, Shariat S, Urologists U. Propensity-score-matched comparison of soft tissue surgical margins status between open and robotic-assisted radical cystectomy. Urologic Oncology Seminars And Original Investigations 2018, 37: 179.e1-179.e7. PMID: 30446442, DOI: 10.1016/j.urolonc.2018.10.012.Peer-Reviewed Original ResearchMeSH KeywordsAgedCarcinoma, Transitional CellChemotherapy, AdjuvantCystectomyFemaleFollow-Up StudiesHumansLength of StayLymph Node ExcisionMaleMargins of ExcisionMiddle AgedPostoperative ComplicationsPropensity ScoreRetrospective StudiesRobotic Surgical ProceduresTreatment OutcomeUrinary BladderUrinary Bladder NeoplasmsConceptsSoft tissue surgical marginsRobotic-assisted radical cystectomyOpen radical cystectomyPositive soft tissue surgical marginsRARC groupSoft tissue surgical margin statusRadical cystectomyPropensity-score matchingRARC patientsOpen radical cystectomy groupImpact of surgical techniqueOpen radical cystectomy patientsNon-organ-confinedMultivariate logistic regression analysisOrgan-confined diseaseSurgical margin statusSubgroup of patientsPropensity-score-matched cohortLogistic regression analysisOncologic efficacySurgical marginsPrognostic factorsUrothelial carcinomaMargin statusSurgical techniqueBOXIT—A Randomised Phase III Placebo-controlled Trial Evaluating the Addition of Celecoxib to Standard Treatment of Transitional Cell Carcinoma of the Bladder (CRUK/07/004)
Kelly J, Tan W, Porta N, Mostafid H, Huddart R, Protheroe A, Bogle R, Blazeby J, Palmer A, Cresswell J, Johnson M, Brough R, Madaan S, Andrews S, Cruickshank C, Burnett S, Maynard L, Hall E, Investigators O. BOXIT—A Randomised Phase III Placebo-controlled Trial Evaluating the Addition of Celecoxib to Standard Treatment of Transitional Cell Carcinoma of the Bladder (CRUK/07/004). European Urology 2018, 75: 593-601. PMID: 30279015, DOI: 10.1016/j.eururo.2018.09.020.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, IntravesicalAgedAntibiotics, AntineoplasticAntineoplastic Combined Chemotherapy ProtocolsBCG VaccineCarcinoma, Transitional CellCardiovascular DiseasesCelecoxibCyclooxygenase 2 InhibitorsDisease ProgressionDouble-Blind MethodFemaleHumansMaleMiddle AgedMitomycinNeoplasm Recurrence, LocalNeoplasm StagingQuality of LifeRisk AssessmentRisk FactorsTime FactorsTreatment OutcomeUnited KingdomUrinary Bladder NeoplasmsConceptsNon-muscle-invasive bladder cancerHigh-risk non-muscle-invasive bladder cancerRisk of recurrenceIncreased risk of cardiovascular eventsRisk of cardiovascular eventsTime to recurrenceCardiovascular eventsNMIBC patientsBladder cancerStandard treatmentPhase III placebo-controlled trialIntermediate-risk non-muscle-invasive bladder cancerNon-muscle-invasive bladder cancer patientsIncreased riskPatients treated with celecoxibWeekly mitomycin C instillationsMitomycin C instillationAdjuvant intravesical therapyRecurrence-free rateMedian follow-upPlacebo-controlled trialTransitional cell carcinomaHigh-risk patientsCyclo-oxygenase 2 inhibitorsIntravesical therapyRadiofrequency-induced Thermo-chemotherapy Effect Versus a Second Course of Bacillus Calmette-Guérin or Institutional Standard in Patients with Recurrence of Non–muscle-invasive Bladder Cancer Following Induction or Maintenance Bacillus Calmette-Guérin Therapy (HYMN): A Phase III, Open-label, Randomised Controlled Trial
Tan W, Panchal A, Buckley L, Devall A, Loubière L, Pope A, Feneley M, Cresswell J, Issa R, Mostafid H, Madaan S, Bhatt R, McGrath J, Sangar V, Griffiths T, Page T, Hodgson D, Datta S, Billingham L, Kelly J. Radiofrequency-induced Thermo-chemotherapy Effect Versus a Second Course of Bacillus Calmette-Guérin or Institutional Standard in Patients with Recurrence of Non–muscle-invasive Bladder Cancer Following Induction or Maintenance Bacillus Calmette-Guérin Therapy (HYMN): A Phase III, Open-label, Randomised Controlled Trial. European Urology 2018, 75: 63-71. PMID: 30274699, DOI: 10.1016/j.eururo.2018.09.005.Peer-Reviewed Original ResearchConceptsNon-muscle-invasive bladder cancerDisease-free survival timeCarcinoma in situBacillus Calmette-GuerinSecond-line therapyTreatment armsComplete responseOpen-labelNo significant differenceBladder cancerCourse of bacillus Calmette-GuerinNon-muscle-invasive bladder cancer patientsBacillus Calmette-Guerin failuresCarcinoma in situ patientsStandard second-line therapyBacillus Calmette-Guerin therapyRecurrence of non-muscle-invasive bladder cancerStandard of care treatmentControlled trialsPapillary bladder lesionsPhase III randomised controlled trialMedian follow-upBladder cancer outcomesSignificant differenceOutcome measuresDoes urinary cytology have a role in haematuria investigations?
Tan W, Sarpong R, Khetrapal P, Rodney S, Mostafid H, Cresswell J, Watson D, Rane A, Hicks J, Hellawell G, Davies M, Srirangam S, Dawson L, Payne D, Williams N, Brew‐Graves C, Feber A, Kelly J, Sridhar A, Lamb B, Ocampo F, McBain H, Baillie K, Middleton K, Knight H, Maher S, Pathmanathan B, Harmathova A, Pelluri S, Pati J, Cossons A, Scott C, Madaan S, Bradfield S, Wakeford N, Dann, Cook J, Cornwell M, Mills R, Thomas, Reyner S, Vallejera G, Adeniran P, Masood S, Whotton N, Dent K, Pearson S, Hatton J, Newton M, Hheeney E, Green K, Evans S, Rogers M, Gupwell K, ley S, Brown A, McGrath J, Lunt N, Hill P, inclair A, Paredes‐Guerra A, Holbrook B, Ong E, Wardle H, Wilson D, Bayles A, Fennelly R, Tribbeck M, Ames K, Taylor J, Edmunds E, Moore J, Mckinley S, Nolan T, peed A, Tunnicliff A, Fossey G, Williams A, George M, Hutchins I, Einosas R, Richards A, Henderson A, Appleby B, Kehoe L, Gladwell L, Drakeley S, Davies J, Krishnan R, Roberts H, Main C, Jain S, Dumville J, Wilkinson N, Taylor J, Thomas F, Goulden K, Vinod C, Green E, Waymont C, Rogers J, Grant A, Carter V, Heap H, Lomas C, Cooke P, Scarratt L, Hodgkiss T, Johnstone D, Johnson J, Allsop J, Rothwell J, Connolly K, Cherian J, Ridgway S, Coulding M, Savill H, Mccormick J, Clark M, Collins G, Jewers K, Keith S, Bowen G, Hargreaves J, Riley K, Rees A, Williams S, Dukes S, Goffe A, Mistry R, Chadwick J, Cocks S, Hull R, oftus A, Baird Y, Moore S, Greenslade S, Margalef J, Chadbourn I, Harris M, Clitheroe P, Connolly S, Hodgkinson S, Haydock H, Storr E, Cogley L, Natale S, Lovegrove W, Slack K, Nash D, Smith K, Walsh J, Guerdette A, Hill M, Taylor B, Sinclair E, Perry M, Debbarma M, Hewitt D, Sriram R, Power A, Cannon J, Devereaux L, Thompson A, Atkinson K, Royle L, Madine J, MacLean K. Does urinary cytology have a role in haematuria investigations? BJU International 2018, 123: 74-81. PMID: 30003675, PMCID: PMC6334509, DOI: 10.1111/bju.14459.Peer-Reviewed Original ResearchMeSH KeywordsAgedCarcinoma, Transitional CellFalse Negative ReactionsFalse Positive ReactionsFemaleHematuriaHumansKidney NeoplasmsMaleMiddle AgedNeoplasm GradingNeoplasm StagingPredictive Value of TestsProspective StudiesTomography, X-Ray ComputedUltrasonographyUreteral NeoplasmsUrinary Bladder NeoplasmsUrineUrographyConceptsUpper tract urothelial cancerPositive urine cytologyAccuracy of urinary cytologyDiagnosis of bladder cancerUrine cytologyHigh-risk cancerNegative predictive valuePositive predictive valueBladder cancerHaematuria investigationsUrinary cytologyInvasive testingDiagnostic accuracy of urinary cytologyMuscle-invasive bladder cancerProspective observational study of patientsMulticentre prospective observational studyObservational study of patientsPredictive valueEndoscopic tumor resectionPositive cytology resultsUpper tract imagingHigh-risk diseaseOutcomes of patientsDiagnosed bladder cancerStudy of patientsCan Renal and Bladder Ultrasound Replace Computerized Tomography Urogram in Patients Investigated for Microscopic Hematuria?
Tan W, Sarpong R, Khetrapal P, Rodney S, Mostafid H, Cresswell J, Hicks J, Rane A, Henderson A, Watson D, Cherian J, Williams N, Brew-Graves C, Feber A, Kelly J, Collaborators D. Can Renal and Bladder Ultrasound Replace Computerized Tomography Urogram in Patients Investigated for Microscopic Hematuria? Journal Of Urology 2018, 200: 973-980. PMID: 29702097, PMCID: PMC6179963, DOI: 10.1016/j.juro.2018.04.065.Peer-Reviewed Original ResearchConceptsUpper tract urothelial cancerComputerized tomography urogramBladder ultrasoundIncidence of bladderUrinary tract cancerMicroscopic hematuriaUrothelial cancerBladder cancerIncidence of upper tract urothelial cancerIncidence of urinary tract cancerRenal calculiPredictive valueUpper tract imagingDetecting bladder cancerNegative predictive valueDetect renal cancerDiagnosed bladder cancerPositive predictive valueSuspected renal calculiHematuria casesMacroscopic hematuriaRenal cancerHematuriaInvestigated patientsCystoscopy